Estrella Immunopharma, Inc. Warrant (ESLAW)

• Market cap: $1.54M
• 1 day: 0.00%
• 5 days: -37.50%
• 1 month: -50.58%
• 3 months: -61.36%
• 6 months: -53.30%
• Year to date: -53.35%
• 1 year: -21.30%
• 5 years: -88.19%
• 10 years: -88.19%
• Sector: Healthcare
• Industry: Biotechnology

About: Estrella Immunopharma Inc is a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors. Estrella's mission is to harness the evolutionary power of the human immune system to transform the lives of patients fighting cancer and autoimmune diseases.

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

0% more repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 1

0.08% less ownership

Funds ownership: 1.93% [Q4 2024] → 1.85% (-0.08%) [Q1 2025]

10% less funds holding

Funds holding: 10 [Q4 2024] → 9 (-1) [Q1 2025]

15% less capital invested

Capital invested by funds: $302K [Q4 2024] → $256K (-$46K) [Q1 2025]

50% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 2